Core Insights - Zimmer Biomet Holdings, Inc. is showcasing its innovations in robotics and musculoskeletal solutions at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS) [1][2] - The company emphasizes the urgency for advanced orthopedic solutions due to an aging population and rising patient expectations for less disruption and faster recovery [3] Product Highlights - The mBôsâ™ TKA System is a CT-based, semi-autonomous robotic technology for total knee arthroplasty that has received FDA 510(k) clearance, with a fully autonomous version in clinical trials [7] - The ROSA Knee with OptimiZe™ is the latest version of the ROSA Knee System, pending FDA clearance, designed to enhance surgical planning and accuracy [7] - The TMINI Miniature Robotic System is a handheld, wireless CT-based robotic system for precise implant placement [7] - ZBEdge Analytics provides intra-operative insights via a smartphone application, allowing surgeons to assess performance and clinical decisions [7] - The mymobility Care Management Platform offers continuous data and patient feedback to improve surgical preparation and recovery [7] - The Oxford Cementless Partial Knee is the only FDA-approved mobile cementless partial knee implant in the U.S., known for its efficiency and survivorship [7] - The Persona OsseoTi Keel Tibia is a cementless tibia for TKA featuring a 3D printed porous tray for stable fixation [7] - The Persona® SoluTion™ PPS® Femur is designed for patients with metal sensitivities, featuring a porous coating for cementless fixation [7] - Persona IQ The Smart Knee captures patient-specific metrics for post-operative insights, enhancing the TKA patient experience [7] Strategic Vision - The company aims to lead in orthopedic innovation by integrating robotics, digital platforms, and AI to improve surgical precision and patient outcomes [3][9] - Zimmer Biomet's commitment to innovation is highlighted as the most ambitious cycle in its history, positioning it to deliver comprehensive orthopedic solutions [3]

Core Insights - Monogram Technologies Inc. has received FDA clearance for its mBôs™ Total Knee Arthroplasty (TKA) System, marking a significant milestone for the company and its technology [4][9] - The company is set to conduct a groundbreaking clinical trial for autonomous saw-based robotic TKA surgeries on live patients, which is expected to demonstrate the potential of robotic precision in surgical procedures [5][9] - Monogram is preparing for initial placements of the mBôs system with key opinion leader surgeons in the U.S. and advancing patient enrollment for the clinical trial in India [6][10] Financial Performance - Research and development expenses decreased by 6% to $2.3 million in Q1 2025, compared to $2.4 million in the same quarter of the previous year [11] - Marketing and advertising expenses saw a significant decrease of 63%, dropping to $44,000 from $120,000 year-over-year [12] - General and administrative expenses were $1.0 million, slightly down from $1.1 million in the prior-year quarter, with a net loss of $3.2 million for Q1 2025, an improvement from a net loss of $3.5 million in Q1 2024 [13] Cash Position - As of March 31, 2025, cash and cash equivalents totaled $13.3 million, down from $15.7 million at the end of 2024, indicating a focus on capital efficiency in commercialization efforts [14] Upcoming Initiatives - The company plans to initiate patient enrollment for the clinical trial and begin the first live patient surgeries in India within 90 business days [9][10] - Monogram is also exploring additional domestic and international partnerships to support the commercialization of the mBôs TKA System [7][10]